Advertisement

Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory Biomarkers for Patients with Stage II/III Colon Cancer

  • Shinsuke Suzuki
  • Takashi AkiyoshiEmail author
  • Koji Oba
  • Fuhito Otsuka
  • Tetsuro Tominaga
  • Toshiya Nagasaki
  • Yosuke Fukunaga
  • Masashi Ueno
Colorectal Cancer

Abstract

Background

Among numerous systemic inflammatory biomarkers, it remains unclear which is the most prognostic for patients with stage II/III colon cancer. We aimed to compare the prognostic significance of systemic inflammatory biomarkers among patients with stage II/III colon cancer.

Methods

We included 1303 patients with stage II/III colon cancer who underwent potentially curative resection from July 2004 to December 2013. Sixteen systemic inflammatory biomarkers—derived from combinations of neutrophils, lymphocytes, monocytes, platelets, C-reactive protein (CRP), and albumin—were compared to identify the biomarker most associated with overall survival (OS) and disease-free survival (DFS) using receiver operating characteristic (ROC) curve analysis.

Results

Nine inflammatory biomarkers were predictive for OS, among which lymphocyte-to-CRP ratio (LCR), CRP-to-albumin ratio (CAR), neutrophil × CRP, monocyte × CRP, and platelet × CRP were also predictive for DFS. Among these five inflammatory biomarkers, the area under the curve (AUC) value was highest (0.630) for LCR, being significantly higher than that for neutrophil × CRP (P = 0.010), monocyte × CRP (P = 0.007), or platelet × CRP (P = 0.010) for OS. When the prognostic impact of LCR and CAR were analyzed by multivariate analysis, only LCR was an independent predictor of both OS [hazard ratio (HR), 1.77; 95% confidence interval (CI), 1.23–2.60; P = 0.002] and DFS (HR, 1.29; 95% CI, 1.00–1.66; P = 0.048).

Conclusions

LCR may be the most useful predictive factor for OS and DFS in patients with stage II or III colon cancer.

Notes

Acknowledgment

This work was supported by a grant-in-aid of the Public Trust Fund for Clinical Cancer Research, and JSPS KAKENHI under Grant Nos. 18K08664 and 18K08635.

Author Contributions

SS and TA designed the study and wrote the manuscript. SS, TA, TT, TN, YF, and MU contributed to data collection. SS, TA, KO, and FO contributed to the analysis and interpretation of data. All authors contributed to analysis and interpretation of data. All authors critically reviewed the manuscript and approved the final version of the manuscript.

Disclosure

The authors declare no conflicts of interest for this article.

Approval of Research Protocol

This retrospective research protocol was approved by the Institutional Review Board of Cancer Institute Hospital (Reference No. 2016-1090), and it conforms to the provisions of the Declaration of Helsinki.

References

  1. 1.
    Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290–1314.CrossRefGoogle Scholar
  2. 2.
    Benson AB, 3rd, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:370–398.CrossRefGoogle Scholar
  3. 3.
    Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–163.CrossRefGoogle Scholar
  4. 4.
    Shibutani M, Maeda K, Nagahara H, et al. The prognostic significance of a postoperative systemic inflammatory response in patients with colorectal cancer. World J Surg Oncol. 2015;13:194.CrossRefGoogle Scholar
  5. 5.
    Pine JK, Morris E, Hutchins GG, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour. Br J Cancer. 2015;113:204–211.CrossRefGoogle Scholar
  6. 6.
    Chan JC, Chan DL, Diakos CI, et al. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg. 2017;265:539–546.CrossRefGoogle Scholar
  7. 7.
    Zou ZY, Liu HL, Ning N, Li SY, Du XH, Li R. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett. 2016;11:2241–2248.CrossRefGoogle Scholar
  8. 8.
    Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K. Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol. 2016;23:900–907.CrossRefGoogle Scholar
  9. 9.
    Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, Horgan PG, McMillan DC. Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer. 2013;109:24–28.CrossRefGoogle Scholar
  10. 10.
    McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534–540.CrossRefGoogle Scholar
  11. 11.
    Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg. 2016;263:326–336.CrossRefGoogle Scholar
  12. 12.
    Koike Y, Miki C, Okugawa Y, et al. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol. 2008;98:540–544.CrossRefGoogle Scholar
  13. 13.
    Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 2018;267:527–531.CrossRefGoogle Scholar
  14. 14.
    Park BK, Park JW, Han EC, et al. Systemic inflammatory markers as prognostic factors in stage IIA colorectal cancer. J Surg Oncol. 2016;114:216–221.CrossRefGoogle Scholar
  15. 15.
    Gomez D, Morris-Stiff G, Wyatt J, Toogood GJ, Lodge JP, Prasad KR. Surgical technique and systemic inflammation influences long-term disease-free survival following hepatic resection for colorectal metastasis. J Surg Oncol. 2008;98:371–376.CrossRefGoogle Scholar
  16. 16.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th edn. New York: Springer; 2010.Google Scholar
  17. 17.
    Rossi S, Basso M, Strippoli A, et al. Are markers of systemic inflammation good prognostic indicators in colorectal cancer? Clin Colorectal Cancer. 2017;16:264–274.CrossRefGoogle Scholar
  18. 18.
    Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg. (2019).  https://doi.org/10.1097/sla.0000000000003239.CrossRefPubMedGoogle Scholar
  19. 19.
    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.CrossRefGoogle Scholar
  20. 20.
    Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer. 2013;109:401–407.CrossRefGoogle Scholar
  21. 21.
    Zhu Y, Zhou S, Liu Y, Zhai L, Sun X. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer. 2018;18:443.CrossRefGoogle Scholar
  22. 22.
    Shinko D, Diakos CI, Clarke SJ, Charles KA. Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine. Clin Pharmacol Ther. 2017;102:599–610.CrossRefGoogle Scholar
  23. 23.
    Dupre A, Malik HZ. Inflammation and cancer: What a surgical oncologist should know. Eur J Sur Oncol. 2018;44:566–570.CrossRefGoogle Scholar
  24. 24.
    Tang H, Li B, Zhang A, Lu W, Xiang C, Dong J. Prognostic significance of neutrophil-to-lymphocyte ratio in colorectal liver metastasis: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0159447.CrossRefGoogle Scholar
  25. 25.
    Wu Y, Li C, Zhao J, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis. World J Surg Oncol. 2016;14:289.CrossRefGoogle Scholar
  26. 26.
    Thomsen M, Kersten C, Sorbye H, et al. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget. 2016;7:75013–75022.CrossRefGoogle Scholar
  27. 27.
    Shibutani M, Maeda K, Nagahara H, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World J Gastroenterol. 2015;21:9966–9973.CrossRefGoogle Scholar
  28. 28.
    Li Y, Jia H, Yu W, et al. Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection. Int J Cancer. 2016;139:220–231.CrossRefGoogle Scholar
  29. 29.
    Choi WJ, Cleghorn MC, Jiang H, Jackson TD, Okrainec A, Quereshy FA. Preoperative neutrophil-to-lymphocyte ratio is a better prognostic serum biomarker than platelet-to-lymphocyte ratio in patients undergoing resection for nonmetastatic colorectal cancer. Ann Surg Oncol. 2015;22 Suppl 3:S603–S613.CrossRefGoogle Scholar
  30. 30.
    Jiang H, Tang E, Xu D, et al. Development and validation of nomograms for predicting survival in patients with non-metastatic colorectal cancer. Oncotarget. 2017;8:29857–29864.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Tokunaga R, Sakamoto Y, Nakagawa S, et al. Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection. Int J Clin Oncol. 2017;22:740–748.CrossRefGoogle Scholar
  32. 32.
    Knijn N, Mogk SC, Teerenstra S, Simmer F, Nagtegaal ID. Perineural invasion is a strong prognostic factor in colorectal cancer: a systematic review. Am J Surg Pathol. 2016;40:103–112.CrossRefGoogle Scholar
  33. 33.
    Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–132.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Gastroenterological SurgeryCancer Institute Hospital, Japanese Foundation for Cancer ResearchTokyoJapan
  2. 2.Department of Biostatistics, Graduate School of MedicineThe University of TokyoTokyoJapan
  3. 3.Statistics Analysis Department, Data Science Division, Development Business HeadquartersEPS CorporationTokyoJapan

Personalised recommendations